Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 10
Submit an article Journal homepage
1,217
Views
40
CrossRef citations to date
0
Altmetric
Research Article

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Ajay K. GopalUniversity of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA, USACorrespondence[email protected]
,
Nancy L. BartlettWashington University School of Medicine, St. Louis, MO, USA
,
Andres Forero-TorresUniversity of Alabama at Birmingham, Birmingham, AL, USA
,
Anas YounesUniversity of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Robert ChenCity of Hope National Medical Center, Duarte, CA, USA
,
Jonathan W. FriedbergJames P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
,
Jeffrey V. MatousColorado Blood Cancer Institute, Denver, CO, USA
,
Andrei R. ShustovUniversity of Washington Medical Center, Seattle, WA, USA
,
Scott E. SmithLoyola University Medical Center, Maywood, IL, USA
,
Jasmine ZainNew York University Cancer Institute, New York, NY, USA
,
Megan M. O’MearaSeattle Genetics, Inc., Bothell, WA, USA
&
Michelle A. FanaleUniversity of Texas M. D. Anderson Cancer Center, Houston, TX, USA
 show all
Pages 2328-2334 | Received 25 Sep 2013, Accepted 10 Dec 2013, Published online: 24 Feb 2014

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Ajay Major, Matthew W. Jackson, Derek E. Smith, Manali Kamdar & Rachel Rabinovitch. (2019) Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leukemia & Lymphoma 60:5, pages 1234-1243.
Read now
Avyakta Kallam & James O. Armitage. (2018) Current and emerging treatment options for a patient with a second relapse of Hodgkin’s lymphoma. Expert Review of Hematology 11:4, pages 293-300.
Read now
Eunhye Oak & Nancy L. Bartlett. (2016) A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Expert Opinion on Drug Safety 15:6, pages 875-882.
Read now
Ana Battle-Lopez, Sonia Gonzalez de Villambrosia, Javier Nuñez, Maria-Luisa Cagigal, Santiago Montes-Moreno, Eulogio Conde & Miguel A Piris. (2016) Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. Expert Review of Anticancer Therapy 16:4, pages 411-421.
Read now
Runzhe Chen & Baoan Chen. (2015) Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma. Drug Design, Development and Therapy 9, pages 1729-1733.
Read now
Mounier Nicolas & Gisselbrecht Christian. (2015) Decision-making in the management of adult classical Hodgkin’s lymphoma: determining the optimal treatment. Expert Review of Hematology 8:2, pages 205-216.
Read now
Árpád Illés, Ádám Jóna & Zsófia Miltényi. (2015) Brentuximab vedotin for treating Hodgkin’s lymphoma: an analysis of pharmacology and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 451-459.
Read now

Articles from other publishers (33)

Arash Letafati, Roben Soheili, Mehdi Norouzi, Parastoo Soleimani & Sayed-Hamidreza Mozhgani. (2023) Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review. Medical Oncology 40:10.
Crossref
Vittorio Ruggero Zilioli, Cristina Muzi, Chiara Pagani, Emanuele Ravano, Erika Meli, Rosa Daffini, Erika Ravelli, Roberto Cairoli & Alessandro Re. (2023) Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review. Cancers 15:5, pages 1515.
Crossref
Daniele Caracciolo, Antonia Mancuso, Nicoletta Polerà, Caterina Froio, Giuseppe D’Aquino, Caterina Riillo, Pierosandro Tagliaferri & Pierfrancesco Tassone. (2023) The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Experimental Hematology & Oncology 12:1.
Crossref
Phoebe T. M. Cheng, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Graham W. Slack, Randy D. Gascoyne, Pedro Farinha, Jeffrey W. Craig, Brian Skinnider, Don Wilson, David W. Scott, Joseph M. Connors, Laurie H. Sehn & Kerry J. Savage. (2022) The outcome of older adults with classic Hodgkin lymphoma in British Columbia. Blood Advances 6:22, pages 5924-5932.
Crossref
A. A. Moccia, S. Aeppli, S. Güsewell, M. Bargetzi, C. Caspar, D. Brülisauer, M. Ebnöther, M. Fehr, N. Fischer, G. Ghilardi, F. Krasniqi, N. Lang, U. Mey, W. Mingrone, U. Novak, C. Pfleger, P. Richter, M. Rütti, A. Schmidt, F. Stenner, M. Voegeli, T. Zander, E. Zucca & F. Hitz. (2020) Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematological Oncology 39:2, pages 196-204.
Crossref
Pei Ting Chen, David Onukogu, Gregory Gotlieb, Rashid Chaudhry, Vijay Jaswani, Karan Josan, Cheema Akhtar & Jen Chin Wang. (2021) HTLV-1-Associated Lymphoma Presented as Massive Lymphadenopathy. Journal of Investigative Medicine High Impact Case Reports 9, pages 232470962110132.
Crossref
Fátima Bayón-Calderón, María L. Toribio & Sara González-García. (2020) Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences 21:20, pages 7685.
Crossref
Satoko Oka, Kazuo Ono & Masaharu Nohgawa. (2020) Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. Anti-Cancer Drugs 31:5, pages 536-539.
Crossref
Jordan Carter, Kevin A. David, Athena Kritharis & Andrew M. Evens. (2020) Current Treatment Options for Older Patients with Hodgkin Lymphoma. Current Treatment Options in Oncology 21:5.
Crossref
Patrik Prša, Betül Karademir, Gökhan Biçim, Hatem Mahmoud, Inbal Dahan, A. Süha Yalçın, Jamal Mahajna & Irina Milisav. (2020) The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics. Biochemical Pharmacology 173, pages 113551.
Crossref
Vittorio Stefoni, Miriam Marangon, Alessandro Re, Arben Lleshi, Maurizio Bonfichi, Antonello Pinto, Nicola Bianchetti, Cinzia Pellegrini, Lisa Argnani & Pier Luigi Zinzani. (2020) Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS. Haematologica 105:10, pages e512.
Crossref
Xiaoli Wang, Elizabeth A. Ludwig, Julie Passarell, Akintunde Bello, Amit Roy & Matthew W. Hruska. (2018) Population Pharmacokinetics and Exposure — Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. The Journal of Clinical Pharmacology 59:3, pages 364-373.
Crossref
Andrew M. EvensRanjana H. AdvaniIrene B. HelenowskiMichelle FanaleSonali M. SmithBorko D. JovanovicGregory R. BociekAndreas K. KleinJane N. WinterLeo I. GordonPaul A. Hamlin. (2018) Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Journal of Clinical Oncology 36:30, pages 3015-3022.
Crossref
Jessica L. Krok‐Schoen, James L. Fisher, Julie A. Stephens, Alice Mims, Sabarish Ayyappan, Jennifer A. Woyach & Ashley E. Rosko. (2018) Incidence and survival of hematological cancers among adults ages ≥75 years. Cancer Medicine 7:7, pages 3425-3433.
Crossref
Nina Prokoph, Hugo Larose, Megan Lim, G. Burke & Suzanne Turner. (2018) Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers 10:4, pages 99.
Crossref
Jonathan W. FriedbergAndres Forero-TorresRodolfo E. BordoniVivian J. M. ClineDipti Patel DonnellyPatrick J. FlynnGregg OlsenRobert ChenAbraham Fong, Yinghui Wang & Christopher A. Yasenchak. (2017) Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood 130:26, pages 2829-2837.
Crossref
Xue Wu, Ping Liu, Haijun Zhang, Yuan Li, Jumah Masoud Mohammad Salmani, Fei Wang, Ke Yang, Rong Fu, Zhewei Chen & Baoan Chen. (2017) Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway. BMC Cancer 17:1.
Crossref
Tyler H. Enos, Lawrence S. Feigenbaum & Heather W. Wickless. (2017) Brentuximab vedotin in CD30 + primary cutaneous T-cell lymphomas: a review and analysis of existing data . International Journal of Dermatology 56:12, pages 1400-1405.
Crossref
Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Armando Santoro, Stefan Hoaus, Gian Matteo Rigolin, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Fioravante Ronconi, Giuseppe Gritti, Daniele Vallisa, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Maria Paola Bianchi, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani & Pier Luigi Zinzani. (2017) Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma. Oncotarget 8:53, pages 91703-91710.
Crossref
Andrea Janíková. (2017) NonHodgkin lymphomas in elderly patients. Onkologie 11:3, pages 128-133.
Crossref
Lesley J. Scott. (2017) Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. Drugs 77:4, pages 435-445.
Crossref
Stephanie Terezakis & John P. Plastaras. 2017. Radiation Therapy in Hematologic Malignancies. Radiation Therapy in Hematologic Malignancies 1 28 .
Letizia Gandolfi, Cinzia Pellegrini, Beatrice Casadei, Vittorio Stefoni, Alessandro Broccoli, Lorenzo Tonialini, Alice Morigi, Lisa Argnani & Pier Luigi Zinzani. (2016) Long‐Term Responders After Brentuximab Vedotin: Single‐Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. The Oncologist 21:12, pages 1436-1441.
Crossref
Nicola J. Stagg, Ben-Quan Shen, Flavia Brunstein, Chunze Li, Amrita V. Kamath, Fiona Zhong, Melissa Schutten & Bernard M. Fine. (2016) Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. Regulatory Toxicology and Pharmacology 82, pages 1-13.
Crossref
Geetika Bhatt, Kami Maddocks & Beth Christian. (2016) CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. Current Hematologic Malignancy Reports 11:6, pages 480-491.
Crossref
Andres Forero-TorresBeata Holkova, Jerome GoldschmidtRobert ChenGregg OlsenRalph V. BocciaRodolfo E. BordoniJonathan W. FriedbergJeff P. Sharman, Maria Corinna Palanca-Wessels, Yinghui Wang & Christopher A. Yasenchak. (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126:26, pages 2798-2804.
Crossref
Jonathan Hebb & Holbrook Kohrt. (2015) Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas. Current Hematologic Malignancy Reports 10:4, pages 438-447.
Crossref
Rajiv S. Magge & Lisa M. DeAngelis. (2015) The double-edged sword: Neurotoxicity of chemotherapy. Blood Reviews 29:2, pages 93-100.
Crossref
M. Gooptu, R. Rhoades & B. Pro. 2015. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma 289 303 .
Anita Kumar, Stefano Pileri, Anas Younes & Andreas Engert. 2015. Hodgkin Lymphoma. Hodgkin Lymphoma 343 354 .
Stephen M. Ansell. (2014) Brentuximab vedotin. Blood 124:22, pages 3197-3200.
Crossref
Francesca Montanari & Catherine Diefenbach. (2014) Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 9:3, pages 284-293.
Crossref
Dennis A. Eichenauer & Andreas Engert. (2014) Antibodies and antibody‐drug conjugates in the treatment of H odgkin lymphoma . European Journal of Haematology 93:1, pages 1-8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.